MAP2K7 and melanoma: As previously reported, RNF44 expression in BRAF inhibitors (BRAFi)-resistant melanoma (BR) cells was increased, and high levels of RNF44 also appeared in BR xenografts and melanoma tumor tissues from BR and BRAFi/MEK inhibitor-resistant melanoma patients [19].